|
|
|
Applied and Environmental Microbiology, October 2004, p . 6306-6308, Vol . 70, No . 10 Intestinal Mucus Alters the Ability of Probiotic Bacteria To Bind Aflatoxin B1 In VitroS . Gratz,1,2 H . Mykkänen,1 A . C . Ouwehand,3,4 R . Juvonen,5 S . Salminen,3 and H . El-Nezami1,2* Department of Clinical Nutrition,1 Food and Health Research Centre,2 Department of Pharmacology and Toxicology, University of Kuopio, Kuopio,5 Department of Biochemistry and Food Chemistry, University of Turku, Turku,3 Danicso Innovations, Kantvik, Finland4 Received 1 February 2004/ Accepted 20 June 2004 ABSTRACT Several probiotics are known to bind aflatoxin B1 (AFB1) to their surfaces and to adhere to intestinal mucus . In this study, preincubation of two probiotic preparations with either AFB1 or mucus reduced the subsequent surface binding of mucus and AFB1, respectively, in a strain-dependent manner . Aflatoxin B1 (AFB1) is an unavoidable food contaminant: current decontamination methods have failed to eliminate aflatoxins from crops . Novel approaches focus on preventing its absorption in the gastrointestinal tracts of animals (15) and humans (4) . Several probiotic bacteria, commonly used in food products, have been shown to bind AFB1 efficiently in vitro (2, 6, 9), but ex vivo results are controversial [3; S . Gratz, H . El-Nezami, and H . Mykkännen, Abstr . 5th Congr . Toxicol . Developing Countries, Guilin, China, abstr . C26, Toxicology 191(Suppl.):50, 2003] . These differences may be caused by intestinal mucus, since several intestinal and probiotic bacteria have been shown to adhere to mucus (8) . Additionally, in vitro studies have focused on bacterial binding sites involved in mucus adhesion (8, 12, 13, 14, 16, 19) and AFB1 adsorption to the bacterial surface (2, 3, 5, 6, 9) . Therefore, the present study investigated whether AFB1 and intestinal mucus influence each other's binding by surface structures of two probiotic preparations . Lactobacillus rhamnosus GG (hereafter referred to as GG) is a potent binder for AFB1 in vitro (1, 5) and ex vivo (3) and for mucus (8, 12) . A mixture of L . rhamnosus LC-705 and Propionibacterium freudenreichii subsp . shermanii JS (LC-705 plus JS), a biopreservative (Bioprofit), showed moderate AFB1 binding in chicks [Gratz et al., Toxicology 191(Suppl.):50, 2003] and was also used in a human study (4) . Both were obtained from Valio, Ltd . (Helsinki, Finland), as lyophilized powder and stored at 80°C . Bacterial counts were determined with a flow cytometer as described previously (1) . Lyophilized bacteria (1, 2.5, or 5 x 1010 CFU) were suspended in 1 ml of phosphate-buffered saline (PBS), incubated for 30 min at 37°C, and centrifuged (7 min, 3,000 x g, and 4°C) prior to use . Crystalline AFB1 (product no . A 6636; Sigma, St . Louis, Mo.) was dissolved in methanol and stored at 20°C . Aqueous AFB1 solutions were prepared in 10 mM PBS (pH 7.4) (2) . Intestinal mucus was collected from three porcine colon samples kindly provided by the University of Kuopio Animal Centre . Mucus was removed and prepared as described previously (12), and protein content was determined with a protein assay kit (Bio-Rad, Espoo, Finland) . Interference in surface binding was assessed in two assays, either by allowing bacteria to bind AFB1 first and subsequently incubating them with mucus or by allowing bacteria to bind mucus first and then incubating them with AFB1 . In the first assay, the bacterial pellet was suspended in aqueous AFB1 solutions of various concentrations (0.32 to 64.1 µM) and incubated (30 min and 37°C) to allow AFB1 binding to the bacterial surface . After centrifugation, the supernatant was analyzed for free AFB1 by reverse-phase high-performance liquid chromatography as described previously (1) . The pelleted complex of bacteria and AFB1 was resuspended in intestinal mucus with different protein concentrations (0.1 to 10 mg of protein per milliliter) and incubated at 37°C for 1 h . Following centrifugation, the supernatant was analyzed for free mucus proteins . As controls, bacteria without AFB1 preincubation were included in the mucus binding assay . The stability of this bacterium-mucus complex was tested by washing the solution with 0.5 ml of Milli-Q water, centrifuging it, and measuring mucus proteins released in the supernatant . To estimate the impact of heat treatment on bacterial mucus binding ability, boiled (1 h in PBS) bacteria were included in the assay . In the second assay, bacteria were incubated with mucus and centrifuged, and the bacterium-mucus complex was resuspended in AFB1 solutions as described above . In order to rule out the possibility that AFB1 binds to the mucus glycoproteins instead of binding to the bacterial surface, AFB1 and mucus were mixed, incubated (1 h at 37°C), and centrifuged, and the amounts of free mucus and free AFB1 were determined . All data are expressed as means of results of four replicates and were analyzed by Student's t test . P values of <0.05 were considered significant . Both GG and LC-705 plus JS were able to remove mucus from the incubation mixture (Fig . 1) . This could be caused by bacterial degradation of mucus, since killing the bacteria with heat disabled mucus binding (data not shown) . However, although lactobacilli (10) and propionibacteria (18) possess proteolytic activity, they do not degrade intestinal mucus (17) . Therefore, surface binding of intestinal mucus must be at least partly involved in mucus removal, since aqueous washing released 30.7% ± 3.9% of bound mucus from LC-705 plus JS and 67.1% ± 1.1% from GG . This finding suggests that intestinal mucus is reversibly bound to the bacterial surface and that the unrecoverable part of mucus may be bound more tightly, hindering the release by aqueous washing . Perhaps more-rigorous washing or sonication could result in greater release of bound mucus . The lower level of mucus binding by LC-705 plus JS is not surprising, since both LC-705 and JS have poor adhesion ability to intestinal mucus and do not influence each other's adhesion capacity in vitro (13, 19), whereas GG was found to adhere well (8, 11, 12, 14, 19) . Furthermore, the mixture LC-705 plus JS also binds AFB1 less efficiently in vitro than GG does (S . Gratz et al., unpublished data) . After preincubation with AFB1, subsequent mucus binding by both probiotics was reduced (Fig . 1), confirming results of Kankaanpää and coworkers (7), who found that AFB1 binding by GG reduced its subsequent adhesion to Caco-2 cells .
Nevertheless, these findings are important, since probiotics adhering to the intestinal wall are less likely to bind and consequently accumulate AFB1 in the host . On the other hand, probiotics with AFB1 bound to their surfaces are less likely to adhere to the intestinal wall and prolong exposure to dietary AFB1 . Hence, specific probiotics may be potent and safe means to reduce absorption and increase excretion of dietary AFB1 from the body .
ACKNOWLEDGMENTS This study was supported by The Academy of Finland (grant 1574) .
REFERENCES
What Is Fermentation?,
What Is Botulism?,
What Is Water Purification?,
What Is Amino Acid?,
What Is Bioengineering?,
e,
Bacteria,
o,
Microbe,
n,
Bacteriology,
r,
Bacterium,
n,
Microbiology,
e,
Escherichia coli,
a,
Microorganism,
i,
Providencia,
s,
Bacteriological,
n,
Streptococci,
c,
Streptococci,
i,
Bactericidal,
e,
Meningococcus,
i,
Antimicrobial,
a,
Microbiological,
r,
Streptococcal,
e,
Antibiotics,
a,
Microbial,
i,
Salmonella,
n,
Biodegradation,
c,
Alcaligenes,
n,
Pseudomonas,
s,
Gram negative,
a,
Bacillus subtilis,
e,
Enterobacters,
i,
Denitrifying
|
© 2005
Transgalactic Ltd (manufacturer of Bioscreen C software) |
Privacy Statement | P.O. Box
1393, 00101 Helsinki, Finland,
Last modified: May 25, 2005
| ||||||